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Dustin B Mangus1, Lei Huang1,2, Patricia M Applegate3, Jason W Gatling1, John Zhang2,1,4 and Richard L Applegate II1*Abstract
Neurocognitive deficits are a major source of morbidity in survivors of cardiac arrest. Treatment options that could
be implemented either during cardiopulmonary resuscitation or after return of spontaneous circulation to improve
these neurological deficits are limited. We conducted a literature review of treatment protocols designed to
evaluate neurologic outcome and survival following cardiac arrest with associated global cerebral ischemia. The
search was limited to investigational therapies that were utilized to treat global cerebral ischemia associated with
cardiac arrest. In this review we discuss potential mechanisms of neurologic protection following cardiac arrest
including actions of several medical gases such as xenon, argon, and nitric oxide. The 3 included mechanisms are:
1. Modulation of neuronal cell death; 2. Alteration of oxygen free radicals; and 3. Improving cerebral hemodynamics.
Only a few approaches have been evaluated in limited fashion in cardiac arrest patients and results show inconclusive
neuroprotective effects. Future research focusing on combined neuroprotective strategies that target multiple
pathways are compelling in the setting of global brain ischemia resulting from cardiac arrest.
Keywords: Cardiac arrest, Global brain ischemia, Neuronal death, Neuroprotection, Resuscitation, Argon, Xenon,
Nitric oxideIntroduction
The leading cause of death after successful cardiopulmo-
nary resuscitation (CPR) following cardiac arrest (CA) is
neurologic injury [1]. In spite of the long-term efforts by
the American Heart Association and related organiza-
tions to update and disseminate resuscitation guidelines,
in-hospital mortality among patients successfully resus-
citated remains near 70% [2,3]. For those patients who
do survive to hospital discharge, neurologic injury ac-
counts for a significant morbidity with nearly 2/3 of pa-
tients having moderate to severe cognitive deficits three
months after CA [4].
The aim of this article is to review strategies that could
potentially be utilized during or after resuscitation to im-
prove survival and neurologic outcome in patients who
suffer CA. Therapeutic hypothermia (TH) is currently* Correspondence: rapplegate@llu.edu
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unless otherwise stated.recommended by the American Heart Association for
comatose patients with restoration of spontaneous circu-
lation (ROSC) after out of hospital cardiac arrest sec-
ondary to ventricular fibrillation/shockable ventricular
tachycardia (Class 1) and is also considered as treatment
for similar patients who suffer in hospital CA and out of
hospital CA caused by non-shockable rhythms [5]. The
beneficial effects of TH have been published in extensive
literature and reviews [6-8] and are not included here. We
seek to evaluate other strategies that, when used individu-
ally or in conjunction with TH, may further improve neuro-
logic outcomes in patients after CA. The interventions
employed during or after CPR that have demonstrated ben-
efits in an animal model of CA may have translation poten-
tial to CA patients and thus perhaps provide significant
survival and neurologic outcome benefits.Literature search method
A literature search was conducted of articles indexed in
Medline and published between 1980 and October 2013
using combinations of keywords including “brain injury”,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Search terms used to perform literature search
Database Search terms
PubMed brain injury
cardiac arrest
neuroprotection
cerebral protection
cardiopulmonary resuscitation
global ischemia
global cerebral ischemia
global brain ischemia
These terms were searched in combinations as subject
headings and keywords simultaneously.
Articles were limited to those printed or translated into English
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“cardiopulmonary resuscitation”, “global ischemia”, “global
cerebral ischemia”, and “global brain ischemia” (Table 1).
Bibliographies of relevant articles were cross-referenced
for pertinent articles. Articles were selected for review if
postulated mechanisms of neuroprotection and some
measure of neurologic outcomes were included. Only neu-
roprotective strategies tested in animal models relevant to
global brain ischemia associated with CA were reviewed.
Case reports, pediatric studies and articles not written in
English were excluded. Studies of therapies administered
before CA were not included as our goal was to investi-
gate potential therapies to improve neurologic outcome
that can be employed in the clinical setting (during or
after CPR). Similarly, the many studies related to neuro-
protection from anesthetic agents were not included, as
administration of anesthetic agents during or immediately
after CPR may be impractical or associated with undesir-
able hemodynamic effects. Due to the pathophysiological
differences between focal and global cerebral ischemia,
the extensive literature regarding neuroprotective strat-
egies in focal cerebral ischemia is acknowledged but not
included in this review. In light of the amount of literature
available, we have divided this review into 2 parts. Part I
of this review (41 articles; Table 2) focuses on approaches
that target an individual stage of the cerebral pathological
cascade after resuscitation from CA.
Review
In CA and resuscitation, the entire brain is subjected to
a transient period of complete ischemia followed by reper-
fusion. The comprehensive cascades of pathophysiology
constituting global brain hypoxic ischemia/reperfusion in-
jury are summarized in Figure 1A. Based on the possible
mechanisms of protection, the literature was separated
into 3 broad mechanistic categories affecting global brain
injury shown in Figure 1B:MODULATING NEURONAL
CELL DEATH PATHWAY(S), INFLUENCING OXY-
GEN FREE RADICALS, OR IMPROVING CEREBRAL
FLUID DYNAMICS.
Modulation of neuronal cell death pathway(s)
A number of processes can ultimately lead to neuronal
injury and cell death following global brain ischemia in-
cluding excitatory amino acid toxicity, metabolic acidosis
and dysregulation of intracellular calcium homeostasis,
protease activation, inflammation and activation of pro-
grammed cell death pathways [9,10]. Strategies that
interrupt the propagation of these cascades would theor-
etically favor neuronal survival.
Anti-excitatory amino acid toxicity
N-Methyl-D-aspartate (NMDA) receptor antagonist Ex-
cessive activation of NMDA receptors under conditionsof energy substrate depletion results in glutamate exci-
totoxicity [11]. This pathology has been demonstrated
in animal models of global brain ischemia [12,13] and
in human patients recovering from CA [14]. Conse-
quently, much effort has gone into targeting glutamate
receptor subtypes in an attempt to limit ischemic brain
damage.
However, in the setting of global brain ischemia, pre
or post CA infusion with the NMDA receptor antagonist
MK-801 exacerbated post-resuscitation neurological def-
icits in the dog model [15]. Similarly post-CA intraven-
ous treatment with the NMDA receptor antagonist GPI
3000 was associated with poor survival and neurologic
function along with increased neuronal death in the neo-
cortex and hippocampus in dogs subjected to CA and
CPR [16]. An interaction between ischemia and com-
petitive NMDA receptor antagonism may be the cause
of deleterious outcomes [15]. Indeed, pharmacological
attempts to use NMDA receptor blockers for stroke
have had very limited clinical success because these
compounds produce additional adverse side effects such
as profound psychotomimetic behavioral changes as well
as intrinsic neurotoxicity at proposed neuroprotective
concentrations [17-19].
Lamotrigine An alternative approach to ameliorate glu-
tamate excitotoxicity can be to inhibit the presynaptic re-
lease of glutamate by using the phenyltriazine seizure
drug lamotrigine. Lamotrigine has been previously shown
to improve survival and neurologic function as well as
hippocampal neurohistopathology up to 21 days in a ger-
bil model of bilateral cerebral artery occlusion [20]. Simi-
lar neuroprotection was consistently found in a rat model
of CA [21]. Lamotrigine administered 15 minutes after
8.5 minutes of CA significantly improved the number of
viable cells compared to non-treated CA rats at 3 weeks
after CA. The mechanism of action of lamotrigine is
Table 2 Summary of neuroprotective strategies for global cerebral ischemia associated with cardiac arrest
Therapy Proposed
mechanism
Study subject Blind Placebo
control
Rando-
mized
Delivery route Effect (positive,
ne ive, neutral)
Outcomes evaluated
Category of Mechanisms I: Modulating neuronal cell death
MK-80115 NMDA antagonist Dogs Yes Yes Yes Intravenous Ne ive Survival16, neurological function15,16;
neurohistopathology15,16
GPI 300016
Lamotrigine21 Inhibition of
glutamate release
Rats Not mentioned Yes Yes Intravenous Po e Neurohistopathology
Xenon26, 30–32 NMDA antagonist Pigs26, 30–32 Yes26, 30–32 Yes26, 30–32 Yes26, 30–32 Inhale26, 30–32 Ear ntervention
(10 inutes post-
RO Neutral26
Neurologic function26, 30–32;
neurohistopathology26, 30,31
Human
(2 ongoing clinical
trials: NCT00879892,
NCT01262729)
Lat tervention
(1 ost-ROSC)
Po e30–32
Argon33,34 Anti-apoptosis Rats Yes Yes Yes Inhale Po e Neurologic function;
neurohistopathology;
Ischemic post-
conditioning 42,43
Anti-apoptosis Pigs Yes Yes Yes Intravenous Po e Survival43; neurological function42,43;
neurohistopathology43;
Left ventricular ejection function42,43
Caspase 3 inhibitor
zDEVD-FMK45
Anti-apoptosis Rats Yes Yes Yes Intracerebro-
ventricular
Ne l Neurologic function;
neurohistopathology
Sodium
bicarbonate48,50–52
Buffering of
metabolic acidosis
Dogs48 Yes48,52 Yes48 Yes48,52 Intravenous Po e for long
car c arrest
(15 inutes) and
ne al for short
car c arrest
(5 utes)48,52
Return of spontaneous
circulation48, 50–52; survival48,50–52;
neurological function48,50–52Humans
(retrospective50,51;
perspective52; ongoing
clinical trial: NCT01377337)
No50,51 No50–52 No50,51
Po e at low
do 1 mEq/kg)
and egative at
hig ose
(>1 Eq/kg)50
Mean arterial pressure and coronary
perfusion pressure48
Po e at high
usa (dose not
spe ied)51
Neurohistopathology48
Carbicarb49 Buffering of
metabolic acidosis
Rats Yes Yes Yes Intravenous Po e at low
do 3 ml/kg);
Ne ive at high
do 6 ml/kg)
Mean arterial pressure; survival;
neurological function;
neurohistopathology
Fluoxetine55 Anti-inflammatory Mice Yes Yes Yes Intravenous Ne l at low
do 10 mg/kg);
Po e at high
do 5 mg/kg)
Neurologic function;
neurohistopathology
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Table 2 Summary of neuroprotective strategies for global cerebral ischemia associated with cardiac arrest (Continued)
Matrix
metalloproteinase-9
inhibitor56
Anti-inflammatory Rats Not mentioned Yes Yes Intraperiton-eal Positive Brain water content;
neurohistopathology
Category of Mechanisms II: Influencing oxygen free-radicals
Hyperoixa (100%)
ventilation57–62
Increased
oxidative stress
Dogs57–60 Not men-tioned57, 59–62 No Yes Inhale Negative57–61 Neurological function57–61;
neurohistopathology58–61;
plasma biomarkers of neuronal
damage62
Pigs61 Yes58 Neutral when co-
treated with
hypothermia and
Negative when not
co-treated with
hypothermia 62
Human62
Methylene blue65–67 Attenuation of
oxidative and
inflammatory
injury
Pigs Not mentioned Yes Yes Intravenous positive Survival65; inflammatory markers65;
neurohistopathology 66; genomics67
Inhaled nitric oxide68,69 Inhibition of
reactive oxygen
species
Mice Not mentioned Yes yes Genotype68 positive Survival68,69; neurological
function68,69;
neurohistopathology68,69;
LVEF68,69; brain edema69;
diffusion weighted imaing69
Inhale69
Nitrite70,71 Reversible
inhibition of
mitochondrial
complex I with
reduced free
radical
production70
Rats70 Yes Yes Yes Intravenous Positive Survival; neurological function;
neurohistopathology
Improved
mitochondrial
function and S-
nitrosylation for
pro-survival71
Mice71
N-acetylcysteine75 Free-radical
scavenger
dogs Yes Yes Yes Intravenous Neutral Neurologic function
Category of Mechanisms III: Improving cerebral hemodynamics
Intrathoracic pressure
during CPR76–79
Improved organ
perfusion
Pigs76,77 Not men-tioned76,77 Yes Yes Intrathoracic
pressure
regulator76
Positive76–79 Survival76–79; neurological
function76–79; brain and heart
blood flow76
Humans78,79 No78 Active
compression-
decompression
device + im-
pedance
threshold de-
vice77–79
Neutral for
neurologic
recovery78Yes
79
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Table 2 Summary of neuroprotective strategies for global cerebral ischemia associated with cardiac arrest (Continued)
Sodium nitroprusside +
active compression/
decompression +
impedance threshold
device80–82
Improved organ
perfusion
Pigs Yes Yes Yes Intravenous Positive Survival and neurological function80;
return of spontaneous circulation
and carotid blood flow81,82; cerebral
perfusion pressure and coronary
perfusion pressure81
Hypertonic saline
hydroxyethyl starch83
Improve
perfusion,
decrease
intracranial
pressure, decrease
brain edema
Rats Yes Yes Yes Intravenous Positive for
cerebral blood
flow during early
reperfuion; neutral
at late time point
(7-day post-
resuscitation)
Survival; cerebral blood flow;
neurological function;
neurohistopathology
Superscript numbers indicate the citation number of studies reviewed.
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Figure 1 Pathophysiology and possible mechanisms of protection following cardiac arrest. A: Comprehensive cascades of pathophysiology
constituting global brain hypoxic ischemia and reperfusion injury following cardiac arrest (CA) and return of spontaneous circulation (ROSC). B: The
possible mechanisms of protection investigated in literature included in this review were separated into three broad mechanistic categories. The
effects of these interventions could decrease global brain injury after resuscitation from cardiac arrest and thus potentially improve survival and
neurologic outcome.
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by blockade of voltage dependent sodium channels [22].
Additionally, decreased sodium influx can prevent intracel-
lular calcium overload, further favoring outcome [23].Xenon The inert gas xenon has both anesthetic proper-
ties and a pharmaceutical profile of low-affinity use-
dependent NMDA receptor antagonism at nonanesthetic
concentrations [24]. It may avoid or reduce adverse side
effects and potential neurotoxicity associated with proto-
typical NMDA receptor antagonists [19,25]. A number
of pre-clinical studies have shown potential utility for
xenon as a neuroprotectant when administered alone or
in combination with TH [26-29]. In a pig model of CA
and CPR, combined mild hypothermia (33 degrees C for
16 hours) with xenon (70% xenon and 30% O2 for
1 hour) showed significantly improved neurologic deficit
scores over 5 days post-ROSC relative to untreated con-
trols [30]. While neuronal viability was similar to mild
TH, combined mild TH + xenon treatment was associ-
ated with less astrogliosis and microgliosis, suggesting
synergistic protection from the combination.
Other xenon studies have been conducted without
combined TH. Pigs underwent 8 minutes of ventricular
fibrillation (VF) arrest followed by 5 minutes of CPR
[31]; one hour after ROSC the pigs were randomized to
70% xenon in 30% O2 for 1 hour or 70% xenon in 30%
O2 for 5 hours or 70% nitrogen in 30% O2 (control). Im-
provement in neurologic function was transient as bene-
fit was only seen in the first 3 post-ischemia days with
no significant difference observed on post-ischemia day
4. At necropsy on day 5, there were significantly reducednumbers of necrotic neurons in pigs ventilated with
xenon [31].
A similar study evaluated pigs receiving 70% xenon/
30% O2 vs. 69% N2/1% isoflurane/30% O2 vs. 70% N2/
30% O2 for one hour starting 10 minutes after ROSC;
findings revealed no differences with respect to neuro-
logic deficit scores over 4 days or neurohistopathological
analysis at day 5 [26].
However, a separate xenon study without TH revealed
that the time to initiate xenon treatment appears to be
critical [32]. Late rather than early treatment with xenon
after CA resulted in neurologic benefit. Xenon 70%/O2
30% administered for one or five hours starting one hour
after ROSC was associated with improved neurologic
function compared to the control group receiving
70% N2/30% O2 [32].
As of this writing, a search of the ClinicalTrials.gov site
for xenon and cardiac arrest reveals that there are two
human clinical trials recruiting subjects (NCT00879892;
NCT01262729). These two clinical trials may provide a
better picture about the translation potential of xenon use
following CA.
Anti-apoptosis
Argon Argon is a non-anesthetic gas that is relatively
cost-effective and available compared to xenon. Intri-
guing data have shown neuroprotective properties of
argon in animal models of global brain ischemia second-
ary to CA. Rats underwent 7 minutes of CA followed by
3 minutes of CPR and one hour after CPR were then
randomized to ventilation with 70% argon/30% O2 vs.
70% N2/30% O2 for one hour [33]. Argon treated rats
had significantly improved neurologic deficit scores for
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pathological outcome in the neocortex and the CA3/4
region of the hippocampus. In a separate pig model of CA
(8 minutes) and CPR (5 minutes), four hour ventilation
with 70% argon/30% O2 after ROSC resulted in signifi-
cantly improved neurologic recovery and less histopath-
ology in brain tissue [34].
In general, the mechanisms of neuroprotection by
argon are poorly understood. The mechanism of neuro-
protection afforded by argon may involve activation of
anti-apoptotic signaling through increasing BcL-xL or
Bcl-2 levels, thus promoting cell survival [35]. Argon
may also affect gamma aminobutyric acid type A recep-
tors, although further data is required to clarify whether
this is the mechanism for cytoprotection [27].
Ischemic post-conditioning (IPC) Although resuscita-
tion requires reperfusion of ischemic tissue with oxy-
genated blood to restore aerobic metabolism and organ
function, reperfusion concomitantly activates multiple
pathogenic mechanisms and results in what is collectively
known as reperfusion injury [23]. At the center of reperfu-
sion injury are mitochondria, playing a critical role as ef-
fectors and targets of injury. Mitochondrial calcium
overload can worsen cell damage by compromising
mitochondrial capability to sustain oxidative phos-
phorylation [36] and by promoting the release of pro-
apoptotic factors [37]. Although interrupting chest
compressions for an extended period during CPR may
lead to poor outcome [38], IPC can limit reperfusion
injury, thus exerting anti-apoptotic effects through
mitochondrial protection [23,39-42]. In pigs subjected
to 15 minutes of VF arrest, IPC was given during the
first 3 minutes of CPR as 4 cycles of 20 seconds of
chest compressions followed by a 20 second pause and
compared to a control group of CPR without IPC.
Both groups received mild TH for 12 hours after CPR.
Left ventricular ejection fraction (LVEF) and neurological
functional recovery were significantly better in the CPR +
IPC group at 2 days compared to regular CPR. The same
investigators further compared the effects of standard
CPR, CPR + IPC, CPR + cardioprotective vasodilator ther-
apy (CVT), or CPR + IPC + CVT [43]. CVT (IV sodium
nitroprusside 2 mg and adenosine 24 mg) was adminis-
tered during the first minute of CPR. CPR + IPC showed
significantly better 48-hour survival, LVEF, neurological
assessment and histological scores compared to the other
groups.
Caspase-3 inhibitor Caspase-3 activation plays a central
role in apoptotic pathways following brain injury [44].
zDEVD-FMK directly interrupts the apoptotic pathway
by inhibiting caspase-3 in focal brain ischemia [45].
However, the same benefits were not observed in thesetting of global ischemia secondary to CA. In a rat
model of CA and CPR, a 7-day intracerebroventricular
(ICV) infusion of the caspase-3 inhibitor zDEVD-FMK
after ROSC did not improve neurologic deficit or neuro-
histopathology at 1, 3 and 7 days [46]. The discrepancy
may be attributed to either whole body ischemia/reperfu-
sion syndrome and/or a systemic inflammatory response
syndrome, which increases the pathological complexity of
brain injury in CA. Additionally, the lack of protective ef-
fects may result from high zDEVD-FMK clearance inside
the ICV system and/or an impaired uptake into the brain
parenchyma [46].
Buffering metabolic acidosis CA prompts a shift to an-
aerobic metabolism leading to rapid development of in-
tense and sustained intracellular acidosis systemically
and locally in the brain. This subsequently triggers a bat-
tery of pathological processes resulting in cytosolic calcium
overload. In the “low flow” or “no flow” state followed by
reperfusion, both CO2 elimination by ventilation and meta-
bolic correction by HCO3 buffering may be necessary to
optimize pH recovery [47]. In this context, buffering meta-
bolic acidosis using sodium bicarbonate (NaHCO3) and
carbicarb have been evaluated as neuroprotective strat-
egies, but the efficacy remains controversial.
After dogs underwent VF arrest for either 5 minutes
(short) or 15 minutes (long), NaHCO3 was administered
as 1 mmol/kg initially with additional doses as necessary
to correct base deficit to −5 mEq/l [48]. Dogs treated
with NaHCO3 demonstrated equivalent rates of ROSC
and 24 hour survival with short arrest but significantly
improved ROSC and survival in the long arrest group
when compared to controls. Acidosis was also signifi-
cantly less in the prolonged arrest group treated with
NaHCO3, while coronary and systemic perfusion pres-
sures were significantly better. Neurologic deficit scores
were improved in both groups treated with NaHCO3,
but histopathologic staining was not different.
Carbicarb is an alkalinizing agent given to combat
acidosis inherent to CA. While NaHCO3 produces in-
creased CO2 and a paradoxical cerebral acidosis, carbi-
carb is a mixture of HCO3 and sodium carbonate that
does not produce paradoxical cerebral acidosis. In a rat
model of CA (8 minutes) and CPR, low dose (3 ml/kg)
carbicarb post-ROSC treatment had positive outcomes
for 7-day survival, neurologic deficits and hippocampal
cell death compared to controls [49]. The protection
was secondary to attenuation of brain pH decreases as
well as an increase in post-resuscitation mean arterial
pressure (MAP). A high dose (6 ml/kg) group com-
pletely neutralized pH but had negative outcomes when
compared to the control group with increased neuronal
cell death, increased neurologic deficit and decreased
MAP [49].
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benefits of NaHCO3 [50,51], but a prospective random-
ized double blind clinical trial did not [52]. In one of the
retrospective human studies, low versus high dose
NaHCO3 administration during resuscitation had no im-
pact on immediate ROSC but low dose NaHCO3 favored
long-term outcomes including survival and neurologic
outcome [51]. The authors found that administering
more than 1 mEq/kg NaHCO3 during CPR had a nega-
tive impact on long-term survival and neurologic out-
come. In another retrospective study associated with the
Brain Resuscitation Clinical Trial III [50], patients were
included in the study if they suffered out of hospital CA
and advanced cardiovascular life support (ACLS) was
initiated within 30 minutes by emergency medical ser-
vices. NaHCO3 administration was optional in the study
and was preferentially more frequently administered at
some institutions than others. Patients treated in the
“high NaHCO3” user sites had significantly better rates
of ROSC and neurologic outcomes. One potential con-
founder in this study is that the patients who received the
higher NaHCO3 doses also had a significantly shorter time
to initiation of ACLS (1.7 minutes). One prospective ran-
domized double-blinded clinical trial in 875 pre-hospital
CA patients showed empirical early administration of
NaHCO3 (1 mEq/kg) had no effect on overall outcomes
in brief (<5 minutes) and moderate (5-15 minutes) CA.
However, there was a trend toward improved outcome
in prolonged (>15 minutes) CA [52].
As of this writing, a search of the ClinicalTrials.gov
site for bicarbonate AND cardiac arrest reveals 1 human
trial that is not yet recruiting subjects (NCT01377337).
This study proposed to investigate the survival at CPR
termination impact resulting from IV administration of
1 mEq/kg NaHCO3 after the first IV dose of epinephrine
and up to 2 additional doses administered at 5 to 10 mi-
nute intervals during CPR.
The discouraging results of attempts to apply this ap-
proach from bench to bedside may be due to opposing
mechanisms of cellular action. High sodium may help by
eliminating H + via the antiporter, but intracellular Na +
accumulation may lead to decreased Ca2+ elimination
via the Na + −Ca2+ exchanger and Ca2+ accumulation
[47]. Ca2+ overload is associated with deleterious cellu-
lar consequences that may compromise anti-acidosis
protective effects. In addition, acidosis depends on the
patient’s medical status before arrest, along with the dur-
ation and efficacy of CPR. Treatment may be improved
by titration guided by venous or arterial pH measure-
ment. Arrest times longer than 15 minutes will most
likely not benefit from bicarbonate administration [47].
Therefore, NaHCO3 was recommended for use during
CA resuscitation in 1974 but was removed from the
CPR algorithm in 1986 secondary to the potential toincrease acidosis. The 1992 and 2000 AHA guidelines
de-emphasized the use of NaHCO3.
Anti-Inflammation
Neuroprotective strategies targeting inflammation have
been investigated extensively in ischemic stroke [53].
Considering persistent systemic inflammatory responses
after CA, anti-inflammation treatment may bring sys-
temic and neurologic benefit favoring improvement in
overall outcomes. Only a few anti-inflammation agents
have been tested in animal models of CA.
Fluoxetine Fluoxetine is a selective serotonin reuptake
inhibitor and has been shown to protect neurons
through anti-inflammatory effects in focal brain ischemia
[54]. In mouse models of CA and CPR, high dose
(10 mg/kg) but not low dose (5 mg/kg) fluoxetine was
associated with decreased histological damage in the
caudate putamen as well as decreased sensorimotor defi-
cits at 3 days when administered 30 minutes after ROSC
[55]. No difference in the hippocampus was observed
with either dose.
Matrix metalloproteinase-9 (MMP-9) inhibitor MMP-
9 activation plays an important role in blood–brain
barrier (BBB) disruption, resulting in brain edema and
inflammation following brain ischemia [53]. SB-3CT is a
specific inhibitor of MMP-9. In a rat model, CA was in-
duced by occlusion of the airway. CPR was started 1 minute
after CA onset. Compared to control CA rats, intraperito-
neal (IP) injections of SB-3CT at 5 minutes after ROSC
was associated with significantly reduced brain tissue ex-
pression of MMP-9 protein and messenger ribonucleic
acid, brain water content, Evans Blue content and cytokine
levels at 3, 9, 24 and 48 hours [56].
Influencing oxygen free radicals
Oxidative stress is a common final mechanism of injury
contributing to brain damage following CA and ROSC. Ex-
cessive production of free oxygen radicals associated with
ischemia and reperfusion injury causes cellular lipid and
protein degradation. Treatments with mechanisms that re-
duce free radicals in the brain may be neuroprotective.
Hyperoxic (100%) ventilation
Hyperoxic (100%) ventilation during CPR and early ROSC
is a traditional component of resuscitation and life support
strategies in CA patients. Emerging animal studies have
challenged the protective role of hyperoxia in the setting
of global brain ischemia with accumulating evidence of
aggravating oxidative damage. Dogs underwent 9 minutes
of CA followed by CPR and were randomized to resus-
citation with normoxia (21% FiO2), hyperoxia (100%
FiO2) or hyperoxia with antioxidant pretreatment [57]. The
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comes at 12 and 24 hours compared to both other groups.
These results were similar to those in dogs that underwent
10 minutes of CA followed by 3 minutes of open chest
CPR and defibrillation [58]. Normoxic dogs were given
room air during CPR and after ROSC were ventilated for
one hour using room air with higher inspired oxygen only
as needed to maintain arterial oxygen between 80 and
100 mm Hg. Hyperoxic dogs were given 100% O2 during
CPR and after ROSC for 1 hour with no FiO2 adjustments.
At 24 hours, dogs resuscitated with 21% O2 showed signifi-
cantly decreased oxidized lipids in the frontal cortex and
significantly better neurologic deficit scores compared to
the hyperoxic dogs [58]. A similar dog study showed a
hyperoxic group had significant increase in neuronal death
and oxidative damage when compared to normoxic resus-
citated (FiO2 21% for one hour, then adjusted to maintain
PaO2 between 80–120 mmHg) and shams at 2 and
24 hours after ROSC [59].
In another dog study, glucose metabolism impairment,
increase in neuronal death and neuroinflammation were
consistently associated with 100% FiO2 ventilation dur-
ing CPR and after ROSC, exacerbating neurologic deficit
[60]. In this study, after ROSC, dogs were ventilated with
either 100% FiO2 or room air for one hour. The hippo-
campi of hyperoxic dogs had decreased utilization of iso-
tope labeled glucose at 2 hours.
Retrospective analysis of data from controls in two
studies evaluating pigs that underwent 8 minutes of CA
followed by CPR was performed [61]. After ROSC, venti-
lation was with 100% FiO2 for 10 minutes or 60 minutes.
Hyperoxic pigs had a significantly increased number of
necrotic neurons and perivascular inflammation at 5 days
after ROSC. There was a trend toward improvement in
neurological deficit in the normoxic group but this did
not reach significance.
There is one prospective, randomized pilot study in
out-of-hospital CA patients with ventricular fibrillation
as an initial rhythm that demonstrated the safety of ven-
tilation with low inspiratory O2 concentration (FiO2 30-
40%) during one hour after ROSC [62]. The use of 100%
FiO2 may worsen neuronal injury during the early post-
resuscitation period in patients not treated by TH [62].
Patients with witnessed out-of-hospital CA were ran-
domized to receive 100% FiO2 or 30% FiO2 for 60 minutes
after ROSC. There was no statistically significant differ-
ence in biomarkers of neuronal injury (neuron-specific
enolase, NSE, and S-100) between groups up to 48 hours
after ROSC. In the subgroup of patients not treated with
TH after arrest, there was a significant decrease in
NSE among the patients treated with 30% FiO2 at
24 hours only. No long-term study has been conducted
to evaluate differences in neurologic outcomes in these
patients.Translational use of reduced inspired O2 for all pa-
tients will be restricted due to the complexity of pre-
morbid conditions and complications associated with
CA. This low FiO2 approach is not feasible in situations
where poor oxygenation is likely to occur, for example
CA associated with pulmonary edema, near drowning,
severe aspiration of gastric contents or pulmonary infec-
tion [62].
Free radical scavengers
Free radical scavengers are drugs that can react with free
radicals and yield nonreactive products. Mixed success
in preclinical studies of various scavengers [63] and early
failures in some clinical trials have diminished early en-
thusiasm [64].
Methylene blue
Methylene blue has been investigated as an antioxidant
in the setting of CA. Methylene blue delivered with a
hypertonic hyperoncotic solution increased 4-hour sur-
vival and decreased plasma inflammatory markers in a
pig model of 12 minutes extended CA and 8 minutes of
resuscitation [65]. The same group further demonstrated
that methylene blue infusion during CPR and continued
for 50 minutes after ROSC significantly prevented the
disruption of the BBB often seen after ischemia and re-
perfusion [66], suggesting decreased nitric oxide metab-
olites. The protective mechanism of methylene blue was
also evaluated using the genomic response to CA and
treatment with methylene blue in the same study design
[67]. This concluded that neuroprotective effects of
methylene blue were diverse, involving regulation of sol-
uble guanylate cyclase and other responses that inhibit
apoptosis and decrease the inflammatory response.
Inhaled nitric oxide
Inhaled nitric oxide (iNO) inhibits and scavenges react-
ive oxygen species. Mice with varied expression of NO
synthase (NOS) underwent 9 minutes of potassium-
induced CA followed by CPR [68]. At 24 hours post re-
suscitation, mice deficient in NOS3 or soluble guanylate
cyclase alpha 1 had significantly poorer outcomes while
NOS3 deficient mice with cardiomyocyte specific over-
expression of NOS3 were protected from the neuro-
logical and cardiac dysfunction. It appears that iNO
works predominantly on soluble guanylate cyclase and
that deficiency of the alpha 1 subunit of this complex
undermines the protective effects of iNO.
In a similar mouse model of CA, iNO (40 ppm) at one
hour after CPR for 23 hours improved neurologic func-
tion at 4 days, LVEF, brain edema and 10-day survival
compared to room air mice [69]. The iNO treatment
also reduced water diffusion abnormality, caspase-3 acti-
vation and cytokine induction [69].
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During hypoxia and ischemia, nitrite is converted to
NO. In a mouse model of 12 minutes of asphyxia in-
duced CA and CPR, significant advantages in survival,
neurologic outcome and cardiac function were found in
mice treated with IV nitrite [70]. There was decreased
mitochondrial oxygen consumption and a reversible spe-
cific inhibition of respiratory chain complex 1 of the
mitochondria, thus tempering oxidative injury. A follow
up study utilized an 8-minute CA model [71]. At 7 days
post-ROSC, rats treated with nitrite had a significant
survival advantage and reduction in the death of CA-1
hippocampal neurons although not associated with signifi-
cant neurologic function benefit. This protection was as-
sociated with improved mitochondrial function after CA
and increased S-nitrosylation for pro-survival signaling.
Regarding clinical applications, establishing the safety
profile of these approaches will be necessary due to the
dual functional role of nitric oxide. By decreasing nitric
oxide metabolites, methylene blue is a potent vasocon-
strictor and thus may have limited clinical utility in
many patients. Nitric oxide or nitrite may induce sys-
temic vasodilation and hypotension that could preclude
their use in CA patients with an unstable hemodynamic
condition.
As of this writing, a search of the ClinicalTrials.gov site
for nitrite and cardiac arrest returns one trial that is recruit-
ing subjects (NCT01189359). This pilot study investigates
the survival following CA impact of 2 micromoles/kg nitrite
infusion during CPR. Early results show hemodynamic and
methemoglobinemia safety at current doses [71].
N-acetylcysteine (NAC)
NAC prevents depletion of glutathione in oxidative in-
jury [72], leading to protection against free radical injury
in the liver and lung [73,74]. However, NAC failed to
show benefits in a clinically relevant large animal model
of global brain ischemia secondary to CA [75]. Dogs
underwent 10 minutes of VF arrest followed by CPR.
NAC (150 mg/kg) treatment upon ROSC did not im-
prove neurologic deficit scores at 23 hours later. Given
that there are many triggers of neuronal injury and more
than one final common pathway of neuronal cell death,
combination therapies may be required to show functional
benefit after global cerebral ischemia. Further pre-clinical
research efforts using NAC in combination with other
neuroprotective agents may still be worth pursuing [75].
Improving cerebral hemodynamics
Intrathoracic pressure modulation during CPR
In order to improve cerebral perfusion, efforts have been
made to enhance CPR efficacy. The mechanical approach
using application of modified active compression-depression
(ACD) CPR assisted by an intrathoracic pressure regulator(ITPR) and an inspiratory impedance threshold device
(ITD) benefitted coronary and cerebral perfusion pressures
in a series of pre-clinical studies.
Pigs that underwent VF arrest for 8 minutes were ran-
domized to regular CPR at 100 compressions per mi-
nutes or CPR with an ITPR, which combines an ITD
with a vacuum source to generate controlled 10 mm Hg
vacuum pressure in the trachea while allowing positive
pressure ventilation [76]. Use of ITPR during CPR im-
proved all hemodynamic parameters including coronary
and cerebral perfusion pressure, blood flow and short-
term survival (24 hour) without compromising oxygen-
ation and blood gases. ITPR + CPR increased coronary
and cerebral perfusion pressures during hypovolemic
CA. Intrathoracic pressure regulation during CPR was
re-evaluated in pigs that underwent 8 minutes of VF ar-
rest followed by either standard CPR (S-CPR) at 80
compressions per minute or ACD CPR at 80 compres-
sions per minute plus an ITD (ACD CPR + ITD) [77].
The ACD CPR + ITD group showed significantly im-
proved coronary and cerebral perfusion pressures and
improved carotid artery blood flow. ACD CPR + ITD
also had significant survival and positive neurologic out-
come advantage at 24 hours post-ischemia when com-
pared to animals that had S-CPR.
Although the results from two human studies are not
conclusive, ACD CPR + ITD may help improve survival
to hospital discharge and short-term neurologic out-
comes. In a prospective controlled trial in Germany, pa-
tients suffering out-of-hospital CA were randomized to
S-CPR or ACD CPR + ITD [78]. Patients in the ACD
CPR + ITD group had significantly improved 1 hour and
24 hour survival rates. There was no significant differ-
ence in the number of patients that survived to hospital
discharge or neurologic score at hospital discharge, al-
though there was a trend towards improved neurologic
score in the ACD CPR + ITD group. A study evaluated
standard chest compressions during CPR versus ACD
CPR + ITD in patients suffering out-of-hospital CA [79].
Survival to hospital discharge with favorable neurologic
outcome was significantly better in the ACD CPR + ITD
group, as was survival to one year. However, neurologic
outcome at one year was similar in all survivors.
Co-administration of the vasodilator sodium nitro-
prusside appears to further enhance cardiovascular and
cerebral hemodynamics [80-82], but these effects have
not been validated in randomized patient studies. So-
dium nitroprusside (SNP)-enhanced CPR (SNPeCPR)
involved ACD CPR with ITD, external application of
abdominal force and 1 mg of nitroprusside injection.
Pigs underwent 6 minutes of VF followed by CPR [81].
Animals were randomized to one of two groups for
15 minutes of CPR: S-CPR or 5 minutes of S-CPR +
SNP then 5 minutes of ACD CPR + ITD + SNP then
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ing (AB). The control group had a significantly worse
ROSC while ACD CPR + ITD + SNP + AB showed sig-
nificantly elevated carotid blood flow when compared
to S-CPR. The addition of SNP to CPR did not signifi-
cantly alter cerebral or coronary perfusion pressures,
but did improve carotid artery blood flow. Using the same
experimental protocol, significantly improved 24-hour
survival, neurologic functional recovery and LVEF were
also found in SNPeCPR pigs compared to S-CPR alone
[80]. The authors suggested the provocative mechanism
was release of nitric oxide causing vasodilation and in-
creasing perfusion to the heart and brain. It is not clear
how much of the benefit was secondary to SNP and how
much to ACD + ITD. The follow-up study from the same
group might help answer this question, although not dir-
ectly addressing neurologic functional recovery [82]. The
study used two protocols. The first protocol randomized
pigs to S-CPR, ACD CPR + ITD, or SNPeCPR. Following
15 minutes of VF arrest, CPR was begun and defibrillation
first attempted at 6 minutes of CPR. SNPeCPR pigs had
significantly better rates of ROSC compared to both other
groups (12/12 vs. 0/6 and 0/6). In the second protocol,
pigs underwent 10 minutes of VF arrest and were then
put into pulseless electrical activity followed by S-CPR or
SNPeCPR. SNPeCPR pigs had significantly improved
ROSC. In both protocols SNPeCPR had enhanced coron-
ary perfusion pressure, carotid blood flow, cerebral perfu-
sion pressure and end-tidal carbon dioxide.
Hypertonic saline hydroxyethyl starch
Early intervention using hypertonic saline hydroxyethyl
starch showed some improvement in cerebral blood flow
but did not ultimately translate to neurologic benefits in
a pre-clinical study using a CA model. The proposed
mechanism is that hypertonic saline hydroxyethyl starch
improves perfusion, decreases intracranial pressure and
decreases brain edema. Rats were exposed to asphyxia
induced CA and resuscitation then randomized to re-
ceive placebo or 7.5% saline/6% hydroxyethyl starch
[83]. The treatment group had increased early cerebral
blood flow, but no improvements in 7-day survival,
neurologic outcome or neuronal cell death were found.
Conclusions
Neurocognitive deficits remain a significant source of
morbidity and mortality in patients who survive cardiac
arrest. Establishing therapeutic options that can be im-
plemented during and after CPR to decrease these
neurologic functional deficits is warranted. In addition
to therapeutic hypothermia, a number of other modal-
ities involving different mechanisms of action have been
tested mainly in the pre-clinical setting using short-term
outcomes. To summarize some preliminary conclusions:1. Xenon and argon modulate neuronal cell death path-
ways, cross the BBB efficiently and have fast onset mak-
ing them good candidates for neuroprotection in the
setting of cardiac arrest but further study is needed to
explore the ideal dosage, initiation time and duration of
their applications; 2. Ischemic post conditioning reduces
reperfusion injury and may be practical for clinical transla-
tion; 3. CPR assisted by active compression-decompression
or intrathoracic pressure regulation favors cerebral perfu-
sion; 4. 100% hyperoxia ventilation appears to be harmful
after resuscitation.
Several approaches have been evaluated in cardiac arrest
patients in limited fashion and the effects on neuroprotec-
tion are inconclusive. In addition to further clinical trials
evaluating therapeutic neuroprotective treatments, the
systemic effects of treatment modalities will also need to
be considered as the effects of cardiac arrest and CPR are
not isolated but rather have diffuse systemic ramifications.
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